<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3333">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03063515</url>
  </required_header>
  <id_info>
    <org_study_id>20161065</org_study_id>
    <nct_id>NCT03063515</nct_id>
  </id_info>
  <brief_title>AchE Inhibitor and Insulin</brief_title>
  <official_title>Using Acetylcholinesterase Inhibitors to Promote Insulin Secretion in Human Beings</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Diabetes Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigator will examine the effect of a single dose of pyridostigmine, AchE inhibitor
      on insulin secretion in healthy subjects. Each subject will undergo an intravenous glucose
      tolerance test (IVGTT) where IV glucose will be administered and the glucose excursion and
      insulin secretion response will be evaluated by measuring insulin and glucose at different
      time points. The test will be carried out twice, once without and once with the
      administration of a single dose of Pyridostigmine on two separate days. The investigator
      hypothesizes that inhibiting AChE will potentiate insulin secretion.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2017</start_date>
  <completion_date type="Anticipated">July 31, 2017</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>First phase insulin response to IV glucose infusion</measure>
    <time_frame>-10, -4, 1, 2, 3, 4, 5, 6, 8, and 10 minutes</time_frame>
    <description>Insulin positive incremental area under the curve and the sum of plasma insulin values at 1 minute and 3 minutes after IV glucose infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucose excursion after IV glucose infusion</measure>
    <time_frame>-10, -4, 1, 2, 3, 4, 5, 6, 8, and 10 minutes</time_frame>
    <description>Glucose positive incremental area under the curve</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>IVGTT without pyridostigmine</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>IVGTT with pyridostigmine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyridostigmine</intervention_name>
    <description>single oral dose of 60 mg pyridostigmine tablet</description>
    <arm_group_label>IVGTT with pyridostigmine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years and older

        Exclusion Criteria:

          -  BMI &gt;30 Kg/m2

          -  fasting glucose &gt;100

          -  Hemoglobin A1C 5.7% or more

          -  History of asthma

          -  Use of medications that may interfere with glucose metabolism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria del Pilar Solano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ada Konway</last_name>
    <phone>305-243-6145</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Diabetes Research Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ada Konway</last_name>
      <phone>305-243-6145</phone>
    </contact>
    <investigator>
      <last_name>Maria del Pilar Solano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 21, 2017</lastchanged_date>
  <firstreceived_date>February 21, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Maria del Pilar Solano</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Insulin secretion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Pyridostigmine Bromide</mesh_term>
    <mesh_term>Cholinesterase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
